FibroGen, Inc (FGEN) VP Pat Cotroneo Sells 95,000 Shares

FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 95,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the completion of the transaction, the vice president now directly owns 173,366 shares of the company’s stock, valued at approximately $8,774,053.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pat Cotroneo also recently made the following trade(s):

  • On Wednesday, August 2nd, Pat Cotroneo sold 28,346 shares of FibroGen stock. The stock was sold at an average price of $33.97, for a total transaction of $962,913.62.
  • On Thursday, July 6th, Pat Cotroneo sold 4,000 shares of FibroGen stock. The stock was sold at an average price of $34.00, for a total transaction of $136,000.00.
  • On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock. The stock was sold at an average price of $32.00, for a total transaction of $96,000.00.
  • On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock. The stock was sold at an average price of $30.00, for a total transaction of $165,000.00.
  • On Monday, June 12th, Pat Cotroneo sold 2,891 shares of FibroGen stock. The stock was sold at an average price of $28.75, for a total transaction of $83,116.25.

FibroGen, Inc (FGEN) traded down 5.84% on Thursday, hitting $41.10. 1,226,276 shares of the company’s stock were exchanged. The company’s market cap is $2.93 billion. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $51.70. The company’s 50-day moving average price is $34.46 and its 200-day moving average price is $28.07.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.01. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29 million during the quarter, compared to analyst estimates of $34.80 million. Analysts forecast that FibroGen, Inc will post ($1.82) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “FibroGen, Inc (FGEN) VP Pat Cotroneo Sells 95,000 Shares” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/2800278/fibrogen-inc-fgen-vp-pat-cotroneo-sells-95000-shares.html.

Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Vanguard Group Inc. boosted its position in shares of FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock valued at $124,409,000 after buying an additional 392,778 shares during the last quarter. BlackRock Inc. boosted its position in shares of FibroGen by 12.3% in the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after buying an additional 546,587 shares during the last quarter. FMR LLC boosted its position in shares of FibroGen by 10.5% in the first quarter. FMR LLC now owns 1,694,574 shares of the biopharmaceutical company’s stock valued at $41,771,000 after buying an additional 161,143 shares during the last quarter. State Street Corp boosted its position in shares of FibroGen by 11.1% in the first quarter. State Street Corp now owns 1,514,465 shares of the biopharmaceutical company’s stock valued at $37,336,000 after buying an additional 150,807 shares during the last quarter. Finally, Janus Capital Management LLC boosted its position in shares of FibroGen by 1.1% in the first quarter. Janus Capital Management LLC now owns 1,363,657 shares of the biopharmaceutical company’s stock valued at $33,613,000 after buying an additional 14,882 shares during the last quarter. Institutional investors and hedge funds own 43.45% of the company’s stock.

A number of research analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Wednesday. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a report on Friday, July 21st. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Leerink Swann reaffirmed an “outperform” rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a report on Tuesday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of FibroGen in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $60.17.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.